Immunotechnology

T cell responses against mutant ras: a basis for novel cancer vaccines
pp. 3-9(7)
Authors: Stubblefield M.A.; Su-Seng P.; Cundy V.A.; Gaudernack G.

Epitope mapping, V-region DNA sequence, and neutralizing Fab fragments of two monoclonal antibodies against the HIV-1 V3 loop
pp. 11-20(10)
Authors: Slattery K.T.; Duarte C.A.; Perez L.; Vazquez J.; Duenas M.; Vilarrubia O.L.; Navea L.; Valdes R.; Reyes O.; Montero M.; Ayala M.; Gavilondo J.

Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers
pp. 21-36(16)
Authors: Wu A.M.; Wengang C.; Raubitschek A.; Williams L.E.; Neumaier M.; Fischer R.; Shi-zhen H.; Odom-Maryon T.; Wong J.Y.C.; Shively J.E.

Identification of epitope recognized by an anti-c-myc monoclonal antibody that cross-reacts with E. coli sigma factor using phage display libraries
pp. 37-46(10)
Authors: Mirdamadi M.; Johnson W.S.; Ikegaki N.; Xao X.T.; Kay B.K.; Kennett R.H.

In vitro and in vivo characterisation of a recombinant carboxypeptidase G₂::anti-CEA scFv fusion protein
pp. 47-57(11)
Authors: Michael N.P.; Chester K.A.; Melton R.G.; Robson L.; Nicholas W.; Boden J.A.; Pedley R.B.; Begent R.H.J.; Sherwood R.F.; Minton N.P.

Meeting report from the 'Therapeutic Antibody Technology 95' meeting -- Not just 'another recombinant antibody meeting'
pp. 59-63(5)
Authors: Gowayed Y.; Wu J.; Barowski L.; Westphall W.; Larrick J.W.; Gavilondo J.

Homogeneous antigen-specific selection of phage displayed antibodies.
pp. 65-65(1)
Authors: Borrebaeck C.A.K.; Malmborg A.C.; Duenas M.; Soderlind E.

Immunotherapy of relapsed B-cell lymphoma with an anti-CD20 antibody (IDEC-C2B8).
pp. 65-66(2)
Author: Grillo-Lopez A.J.

Production of secretory IgA antibodies in plants.
pp. 66-66(1)
Author: Hein M.B.

Monoclonal antibodies for the treatment of solid tumors.
pp. 66-67(2)
Authors: Hellstrom I.; Hellstrom K.E.

Anti-colorectal cancer antibodies by phage display.
pp. 67-67(1)
Authors: Hoogenboom H.R.; de Bruine A.; Arends J.-W.

Perfecting single-chain Fv imaging agents.
pp. 67-68(2)
Authors: Huston J.S.; George A.J.T.; Jamar F.; Adams G.P.; M.-S. T.; McCartney J.E.; Houston L.L.; Oppermann H.; Heelan B.T.; Peters A.M.; Weiner L.M.

Design, expression and 3-D structure of bifunctional single chain Ig-like molecules.
pp. 68-68(1)
Authors: Hudson P.; Atwell J.; Colman P.; Dougan D.; Gruen C.; Kortt A.; Malby R.; McCoy A.; Pearce L.; Power B.; Tulloch P.

Rapid diagnosis of HIV1 and HIV2 using recombinant Fab and, extended scFvs.
pp. 68-69(2)
Authors: Lilley G.G.; Coia G.; Dolezal O.; Kortt A.A.; Hudson P.J.

Phage-display library selection and mutation for the engineering of antibody affinity.
pp. 69-69(1)
Authors: Irving R.; Dolezal O.; Coia G.; Holliger P.; Gruen C.; Kortt A.; Waldmann H.; Hudson P.

Genetically engineered antibodies with improved functional properties.
pp. 69-70(2)
Authors: Morrison S.L.; Coloma M.J.; Harvill E.T.

Trinucleotide-directed mutagenesis (TRIM) and 2nd generation mini-antibodies.
pp. 70-70(1)
Authors: Pack P.; Ilag V.; Hardt C.; Rheinnecker M.; Wellnhofer G.; Virnekas B.

Humanized anti-CD11a: research and clinical perspectives.
pp. 70-71(2)
Authors: Presta L.; Blank G.; Jardieu P.

RSHZ19, a reshaped human Mab for the treatment and prevention of severe RSV infection.
pp. 71-71(1)
Authors: Porter T.; Dillon S.; Rosenberg M.

Engineering ultra high affinity human anti-c-erbB-2 single-chain Fv using phage display.
pp. 71-72(2)
Authors: Schier R.; McCall A.; Marks J.D.

Human antibody libraries.
pp. 72-73(2)
Authors: Vaughan T.J.; Williams A.J.; Pritchard K.; Osbourn J.K.; Pope A.R.; Earnshaw J.C.; McCafferty J.; Wilton J.; Johnson K.S.

Determinants of selective tumor targeting by single-chain Fv molecules.
pp. 73-73(1)
Authors: Weiner L.M.; Marks J.; Huston J.; Schier R.; McCartney J.; Wolf E.J.; von Mehren M.; Adams G.P.

'Knobs-into-holes' provides a rational design strategy for engineering antibody C_H3 domains for heavy chain heterodimerization.
pp. 73-73(1)
Authors: Carter P.; Ridgway J.B.B.; Presta L.G.